Clinical implementation of integrated molecular‐morphologic risk prediction for meningioma-Reference-Cited by-同舟云学术

Clinical implementation of integrated molecular‐morphologic risk prediction for meningioma

Published:2022-11-14 Issue:3 Volume:33 Page:
ISSN:1015-6305
Container-title:Brain Pathology
language:en
Short-container-title:Brain Pathology

Author:

Hielscher Thomas¹,Sill Martin²,Sievers Philipp³,Stichel Damian³,Brandner Sebastian⁴⁵^ORCID,Jones David T. W.²⁶,von Deimling Andreas³,Sahm Felix³,Maas Sybren L. N.⁷⁸^ORCID

Affiliation:

1. Department of Biostatistics German Cancer Research Center (DKFZ) Heidelberg Germany

2. Hopp Children's Cancer Center Heidelberg (KiTZ) Heidelberg Germany

3. Department of Neuropathology, University Hospital Heidelberg and CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK) German Cancer Research Center (DKFZ) Heidelberg Germany

4. Division of Neuropathology, National Hospital for Neurology and Neurosurgery University College London NHS Foundation Trust London UK

5. Department of Neurodegenerative Disease, Queen Square Institute of Neurology University College London London UK

6. Division of Pediatric Glioma Research German Cancer Research Center (DKFZ) Heidelberg Germany

7. Department of Pathology Leiden University Medical Center Leiden The Netherlands

8. Department of Pathology Erasmus Medical Center Rotterdam The Netherlands

Funder

Deutsche Krebshilfe

Gemeinnützige Hertie‐Stiftung

Publisher

Wiley

Subject

Neurology (clinical),Pathology and Forensic Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bpa.13132

Reference21 articles.

1. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018

2. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

3. TERT Promoter Mutations and Risk of Recurrence in Meningioma

4. CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas

5. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma;Nature Medicine;2024-08-21

2. The Impact of Molecular and Genetic Analysis on the Treatment of Patients with Atypical Meningiomas;Diagnostics;2024-08-15

3. Loss over 5% of chromosome 1p is a clinically relevant and applicable cut-off for increased risk of recurrence in meningioma;Acta Neuropathologica;2024-08-08

4. Clinical implications of DNA methylation-based integrated classification of histologically defined grade 2 meningiomas;Acta Neuropathologica Communications;2024-05-08

5. Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients;Neuro-Oncology;2024-05-02